Company Overview
Sana Biotechnology, Inc. operates within the healthcare sector as a biotechnology firm that focuses on utilizing engineered cells as medicines in the United States to address unmet treatment needs. The company develops ex vivo and in vivo cell engineering platforms primarily for therapeutic areas such as type 1 diabetes and B cell mediated autoimmune diseases. In terms of scale, the company holds a market capitalization of $843.30M and maintains an employee count of 142 individuals. The available financial data indicates that annual revenue is not disclosed in the provided facts, which suggests the company is likely in a pre-revenue or early-stage revenue generation phase typical for biotechnology firms focused on developing novel cell engineering technologies. This specific market capitalization relative to the lack of disclosed revenue highlights that the company's valuation is driven by future potential and intellectual property rather than current earnings or sales volume. The relatively small workforce of 142 employees further contextualizes the company's operational scale, indicating a lean organization typical of early-stage biotech entities where human capital is concentrated on research and development rather than large-scale commercial operations.
Financial Health
The financial profile of Sana Biotechnology, Inc. reflects significant operational losses, with a net income (TTM) of $-244,166,000 and an EBITDA of $-178,208,000. The reported revenue (TTM) is listed as N/A, meaning no specific revenue figure is available for analysis, yet the substantial negative net income reveals a cost structure where expenses vastly exceed any potential or current income. The company generated a free cash flow of $-53,566,752, which indicates a heavy reliance on external capital sources to fund ongoing operations and research activities without generating internal liquidity. All three margin metrics—gross margin, operating margin, and profit margin—are reported at 0.0%, which in the context of a biotechnology company often signifies that revenue figures are either non-existent or insufficient to cover the high costs of goods sold and operating expenses, resulting in zero profitability. On the balance sheet, the company holds $138.38M in cash against $86.26M in debt, supported by a debt-to-equity ratio of 53.62, which suggests a highly leveraged position relative to its equity base. Despite the high leverage indicated by the debt-to-equity ratio, the current ratio stands at 1.89, indicating that the company possesses sufficient current assets to cover its short-term liabilities with nearly double the necessary liquidity. Return on Equity is reported at -118.7% and Return on Assets at -26.0%, metrics that reveal management is currently destroying shareholder value and utilizing assets inefficiently due to the company's deep losses.
Valuation Assessment
Valuation metrics for Sana Biotechnology, Inc. present a complex picture due to the absence of traditional profitability measures. The trailing P/E ratio is listed as N/A because the company has no positive earnings to support a calculation, while the forward P/E is reported at -5.17, implying that analysts or data providers project continued negative earnings growth rather than a path to immediate profitability. The price-to-book ratio is 5.24, which indicates that the market values the company at more than five times its book value, suggesting a significant premium attached to its intangible assets, pipeline potential, or proprietary cell engineering platforms. Since revenue is N/A, the price-to-sales ratio is also N/A, and the EV/EBITDA stands at -4.37, further confirming that traditional valuation multiples based on earnings or sales are not applicable in the conventional sense. The stock has traded with a 52-week high of $6.55 and a 52-week low of $1.26, meaning the current price sits somewhere within this wide range, reflecting high uncertainty and volatility typical for companies without positive earnings. The beta value of 1.96 indicates that the stock is nearly twice as volatile as the broader market, suggesting that price movements will be amplified relative to general market trends.
Growth & Income
Growth and income metrics for Sana Biotechnology, Inc. are characterized by the absence of historical financial performance data rather than a lack of potential. Revenue growth (YoY) and earnings growth (YoY) are both listed as N/A, which precludes any calculation regarding whether earnings are growing faster or slower than revenue because no revenue baseline exists. The company does not pay dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, indicating that the firm reinvests all available resources into research and development rather than distributing income to shareholders. Consequently, the overall growth and income profile is defined entirely by the company's ability to transition from its current loss-making stage to a profitable one, with no current contribution to shareholder income through dividends. The lack of a payout ratio confirms that the company is not in a stage where it can sustainably pay dividends given its net income of $-244,166,000. This reinvestment strategy is standard for biotechnology companies that prioritize advancing their ex vivo and in vivo cell engineering platforms over returning capital to investors.